DalsnaFinance

PT

Protagonist Therapeutics Inc $PTGX

Health Care

Russell 2000

Create a scorecard

Live price temporarily unavailable.

Price history

Loading chart…

Protagonist Therapeutics Inc (PTGX) is a Health Care company in the Russell 2000. Latest news and coverage below.

IPO: August 11, 2016 · $12.00 offering · NASDAQ · View IPO details →

Recent News (6)

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model? Yahoo Finance · 04 Sep 2026 MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
Protagonist Therapeutics stock rating maintained at Buy by Clear Street Investing.com · 31 Aug 2026 Protagonist Therapeutics stock rating maintained at Buy by Clear Street
Jefferies reiterates Protagonist Therapeutics stock rating on Mimrylo label strength Investing.com · 31 Aug 2026 Jefferies reiterates Protagonist Therapeutics stock rating on Mimrylo label strength
Protagonist Therapeutics receives FDA approval for polycythemia vera drug Investing.com · 29 Aug 2026 Protagonist Therapeutics receives FDA approval for polycythemia vera drug
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) The Globe and Mail · 22 Jul 2026 Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) The Globe and Mail · 22 Jul 2026 Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB) The Globe and Mail

More Health Care stocks

Browse all companies →